Log In
Print
BCIQ
Print
Print this Print this
 

Nitoman, Xenazine, tetrabenazine

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionSelective inhibitor of vesicular monoamine transporter (VMAT2)
Molecular Target Vesicular monoamine transporter 2 (VMAT2) (SLC18A2)
Mechanism of ActionVesicular monoamine transporter 2 inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHuntington's disease (HD)
Indication DetailsTreat chorea associated with Huntington's disease (HD)
Regulatory Designation Japan - Orphan Drug (Treat chorea associated with Huntington's disease (HD))
Partner Chiesi Farmaceutici S.p.A.; EUSA Pharma; H. Lundbeck A/S; Temmler Pharma GmbH & Co. KG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$1,310.0M

$1,010.0M

$300.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today